Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the impact of the Accu-Chek SmartGuide continuous glucose monitoring CGM device in adults with Type 1 or insulin-dependent Type 2 diabetes who use multiple daily insulin injections. The trial compares the time their blood glucose levels stay within the target range of 70 to 180 mgdL when using the CGM device versus traditional self-monitoring of blood glucose SMBG. This open-label, randomized study aims to gather data on glucose management improvements with the new device. Participants are assigned to one of two groups one group uses the Accu-Chek SmartGuide CGM solution, which includes a sensor, a device, and smartphone apps that provide real-time glucose readings and data analysis. The control group continues using SMBG with a blinded CGM sensor during assessment periods, meaning they cannot see real-time glucose data. The study includes baseline and multiple assessment periods over 26 weeks to measure changes in glucose control markers. During the study, participants will have their blood glucose levels monitored and compared across different periods using the CGM or SMBG methods. Researchers will collect data on time spent within glucose target ranges, hypoglycemia and hyperglycemia events, average glucose levels, insulin doses, carbohydrate intake, and questionnaire scores related to diabetes distress and fear of hypoglycemia. The study lasts approximately 27 weeks, including baseline and three assessment periods, with multiple visits and data collection to understand the devices impact on glucose management.
Actively Recruiting
Researchers are evaluating the effects of intravenous ferric carboxymaltose FCM compared with a placebo on death risk, heart failure events, NT-proBNP levels, and quality of life in patients who recently had an acute myocardial infarction AMI and have iron deficiency. This phase 4, multicenter, randomized, double-blind, placebo-controlled clinical trial aims to assess these outcomes over a follow-up period ranging from 8 to 36 months. Participants are randomly assigned to receive either an intravenous 15-minute infusion of 1000 mg FCM diluted in saline or a placebo infusion of saline alone. The first dose is given on the day of randomization, with follow-up visits at 4, 8, 12, 18, 24, and 30 months to reassess participants and possibly repeat treatment if safety criteria are met. During the study, participants undergo evaluations including monitoring of death rates, heart failure events such as unplanned hospitalizations or emergency visits, changes in NT-proBNP concentration, and quality of life measured by the EQ-5D questionnaire. Safety and treatment effects are tracked throughout the follow-up period, which can last up to 36 months from the start of participation.